Interferon-α is able to maintain complete molecular remission induced by imatinib after its discontinuation

被引：0
|
作者：
A M Carella
机构：
[1] Azienda Ospedaliera Universitaria San Martino,Division of Hematology
来源：
Leukemia | 2008年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1090 / 1091
页数：1
相关论文
共 50 条
  • [31] Follow-up of complete cytogenetic remission in chronic myeloid leukemia patients after cessation of interferon-α.
    Mahon, FX
    Delbrel, X
    Cony-Makhoul, P
    Fabères, C
    Pigneux, A
    Marit, G
    Bilhou-Nabera, C
    Bernard, P
    Boiron, JM
    Reiffers, J
    BLOOD, 1999, 94 (10) : 530A - 530A
  • [32] A More Sensitive RQ-PCR to Assess Complete Molecular Remission Does Not Allow the Prediction of Relapse After Discontinuation of Imatinib In Chronic Myeloid Leukemia.
    Mahon, Francois-Xavier
    Dulucq, Stephanie
    Guilhot, Francois
    Legros, Laurence
    Rousselot, Philippe
    Belanger, Coralie
    Etienne, Gabriel
    Reiffers, Josy
    Rea, Delphine
    BLOOD, 2010, 116 (21) : 948 - 948
  • [33] Sustained Molecular Response with Maintenance Dose of Interferon Alfa After Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia
    Usuki, Kensuke
    Yusa, Nozomi
    Hangaishi, Akira
    Sekine, Rieko
    Suzuki, Kenshi
    Kimura, Shinya
    Tojo, Arinobu
    BLOOD, 2012, 120 (21)
  • [34] Durable molecular complete remission induced by low-dose imatinib plus low-dose interferon alpha in a patient with chronic myelogenous leukaemia
    Takeuchi, J
    Miura, K
    Hatta, Y
    Sawada, U
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2006, 34 (01) : 103 - 108
  • [35] Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib
    Norbert Frickhofen
    Elisabeth Märker-Hermann
    Andreas Reiter
    Christoph Walz
    Bernd Jung
    Heidi Bauer
    Andreas Hochhaus
    Annals of Hematology, 2004, 83 : 477 - 480
  • [36] IMATINIB DISCONTINUATION AFTER IMATINIB/INTERFERON ALPHA COMBINATION THERAPY IS ASSOCIATED WITH CONTINUOUS RESPONSES IN THE MAJORITY OF PATIENTS
    Hochhaus, A.
    Neubauer, A.
    Mueller, M. C.
    Napieralski, S.
    Erben, P.
    Bostel, T.
    Hehlmann, R.
    Burchert, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 369 - 369
  • [37] To the editor: Discontinuation of imatinib therapy after achieving a molecular response
    Cortes, J
    O'Brien, S
    Kantarjian, H
    BLOOD, 2004, 104 (07) : 2204 - 2205
  • [38] How cured are CML patients in complete molecular remission (CMR) after stem cell transplantation or imatinib?
    Simoes, Manuel S.
    Score, Joannah
    Cross, Nicholas C. P.
    Apperley, Jane F.
    Melo, Junia V.
    BLOOD, 2007, 110 (11) : 306A - 306A
  • [39] Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib
    Frickhofen, N
    Märker-Hermann, E
    Reiter, A
    Walz, C
    Jung, B
    Bauer, H
    Hochhaus, A
    ANNALS OF HEMATOLOGY, 2004, 83 (07) : 477 - 480
  • [40] Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
    Mahon, Francois-Xavier
    Rea, Delphine
    Guilhot, Joelle
    Guilhot, Francois
    Huguet, Francoise
    Nicolini, Franck
    Legros, Laurence
    Charbonnier, Aude
    Guerci, Agnes
    Varet, Bruno
    Etienne, Gabriel
    Reiffers, Josy
    Rousselot, Philippe
    LANCET ONCOLOGY, 2010, 11 (11): : 1029 - 1035
12345